Your session is about to expire
← Back to Search
Clinical Decision Support System for HIV Prevention (PrEDICT Trial)
N/A
Waitlist Available
Led By Julia Marcus, PhD
Research Sponsored by Harvard Pilgrim Health Care
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will test whether an electronic health record (EHR)-based clinical decision support system that incorporates an HIV risk prediction model can help providers identify patients at increased risk for HIV infection and improve PrEP prescribing in safety-net community health centers.
Who is the study for?
This trial is for primary care providers at selected clinics who are licensed to prescribe HIV prevention medication known as PrEP. There are no specific exclusion criteria mentioned, so it appears open to all eligible healthcare professionals in the participating locations.
What is being tested?
The study is testing an electronic tool designed to help doctors identify patients at higher risk of HIV and decide if they should be offered PrEP. It compares usual practices with using this new decision support system in community health centers.
What are the potential side effects?
Since this trial focuses on a decision support tool rather than a medical treatment, there aren't direct side effects like those associated with drugs or therapies. However, the impact on patient care and prescription patterns will be closely monitored.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
PrEP prescriptions
Secondary study objectives
Acceptability of clinical decision support system
Feasibility of clinical decision support system
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Active Control
Group I: Arm 1 - Standard of careActive Control1 Intervention
Standard of care
Group II: Arm 2 - Clinical decision support for PrEPActive Control1 Intervention
EHR-based decision support tools to support PrEP discussions and prescribing for patients who have increased predicted HIV risk
Find a Location
Who is running the clinical trial?
OCHIN, Inc.OTHER
22 Previous Clinical Trials
8,725,121 Total Patients Enrolled
National Institute of Mental Health (NIMH)NIH
2,928 Previous Clinical Trials
2,745,015 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
1,006 Previous Clinical Trials
7,414,108 Total Patients Enrolled
Harvard Pilgrim Health CareLead Sponsor
59 Previous Clinical Trials
24,986,069 Total Patients Enrolled
Beth Israel Deaconess Medical CenterOTHER
859 Previous Clinical Trials
12,932,492 Total Patients Enrolled
Julia Marcus, PhDPrincipal InvestigatorHarvard Pilgrim Health Care Institute
Douglas Krakower, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center
2 Previous Clinical Trials
138 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a licensed provider who can prescribe PrEP at a participating clinic.N/A
Research Study Groups:
This trial has the following groups:- Group 1: Arm 1 - Standard of care
- Group 2: Arm 2 - Clinical decision support for PrEP
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.